Full Press Release Details
Quarter 2018 Financial Results
filed for UCART22 clinical investigation in ALL patients
takes over Pfizer's rights under the Research and License Agreement
with Cellectis, to accelerate development and commercialization of
allogeneic off-the-shelf UCART therapies
Wyss Institute partners with Cellectis to recode the human genome
using TALEN gene editing technology
position of $282 million as of March 31, 2018
position above $450 million after taking into consideration the
$190.5 million total gross proceeds from its follow-on offering of ADSs
NEW YORK--(BUSINESS WIRE)--May 7, 2018--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq:
CLLS), a clinical-stage biopharmaceutical company focused on developing
immunotherapies based on gene-edited allogeneic CAR T-cells (UCART),
announced today its results for the three-month period ended March 31,
"2018 is off to a strong start for Cellectis and the message is clear -
off-the-shelf, gene edited CAR T-cells are the next wave of innovation
in oncology. As leaders and pioneers of this space, we continue to show
our excellence, notably in manufacturing, which is a critical segment of
the value chain, with the completion of the production of a 3rd
UCART product, UCART22, enabling the recent IND filing in ALL. We are
also excited about the ongoing clinical development of UCART123 in
high-risk AML and BPDCN patients, and we will aim to accelerate our
clinical trial timelines. Finally, after close to 4 years of a rewarding
and productive partnership with Pfizer, Cellectis is thrilled by the
assumption of this partnership by Allogene Therapeutics, Inc., which is
a new company that was formed by Dr. Arie Belldegrun and Dr. David
Chang, former top executives of Kite Pharmaceuticals. We believe that
our collaboration with Allogene opens a huge opportunity to accelerate
the development of certain of our allogeneic CAR T-cells that were
developed together with Pfizer and Servier," said Andr Choulika,
Chairman and Chief Executive Officer, Cellectis.
"Furthermore, we are humbled by our recent partnership with Prof. George
Church and Harvard's Wyss Institute, utilizing the TALEN
gene editing technology in the Genome Recode Project-a project to recode
the human genome and create the first ever virus-resistant human cells.
This milestone project of modern biology will influence the future of
gene editing in human science in this 21st Century."
1 Cash position includes cash, cash equivalent and current
RECENT CORPORATE HIGHLIGHTS
Cellectis - Therapeutics
IND filing for UCART22 in Acute Lymphoblastic Leukemia (ALL)
On May 2, 2018, Cellectis filed an IND with the FDA for its UCART22
product candidate to be investigated in a Phase I clinical trial in ALL
patients. This submission marks the third UCART product candidate IND
Harvard's Wyss Institute partnership on Human Recode Project, part
On May 1, 2018, Cellectis announced that the Recode Project, a part of
Genome Project-Write, will use Cellectis' TALEN gene editing technology
to seek to create the first virus-resistant human cells for
manufacturing therapeutics and develop new cell-based therapies. The
cell lines would be engineered to be able to carry out their normal
functions while being resistant to debilitating viral infections, and
could offer synthetic biologists opportunities for engineering entirely
new functions. The Recode Project is led by Prof. George Church, Core
Faculty member at the Wyss Institute, Professor of Genetics at Harvard
Medical School (HMS) and of Health Sciences and Technology at Harvard
and the Massachusetts Institute of Technology (MIT).
Strategic collaboration with Allogene Therapeutics, Inc.
On April 3, 2018, Pfizer, Inc. ("Pfizer") and Allogene Therapeutics,
Inc. ("Allogene") entered into an asset contribution agreement, the
closing of which was announced on April 9, 2018, pursuant to which
Allogene purchased Pfizer's portfolio of assets related to allogeneic
CAR T-cell therapy (the "Asset Contribution Transaction"), including the
Research Collaboration and License Agreement dated June 17, 2014 (as
amended from time to time, the "Collaboration Agreement") signed between
Pfizer and Cellectis. Cellectis remains eligible to receive clinical and
commercial milestone payments of up to $2.8 billion, or $185 million per
target for 15 targets, and tiered royalties in the high single digits on
net sales of any products that are commercialized by Allogene under the
Collaboration Agreement. As part of the Asset Contribution Transaction,
Allogene has received Pfizer's rights to UCART19, which were
sub-licensed to Pfizer by Les Laboratoires Servier ("Servier"), which
has an exclusive license to UCART19 from Cellectis under the Product
Development, Option, License and Commercialization Agreement between
Servier and Cellectis dated as of February 17, 2014.
We believe that this alliance with Allogene's dedicated team will lead
to a strong acceleration of CAR T therapies.
$190.5 million raised in a follow-on offering
On April 10, 2018, Cellectis closed a follow-on offering of 5,646,000
American Depositary Shares, each representing one ordinary share of
Cellectis ("ADS"), at a public offering price of $31.00 per ADS.
Cellectis today announced that on May 4, 2018, the underwriters
partially exercised their option to purchase additional ADSs with
respect to 500,000 additional ADSs (the "Option"), under the same terms
and conditions as the initial offering completed on April 10, 2018 of
5,646,000 ADSs at a public offering price of $31.00 per ADS. The
settlement-delivery of the Option is contemplated on May 11, 2018,
subject to customary conditions.
The gross proceeds for the Option are $15.5 million, bringing the total
gross proceeds for the follow-on offering, as increased by the Option,
to $190.5 million, before deducting the expenses related to the offering
and the underwriting discounts and commissions payable by Cellectis.
The ADSs are listed on the Nasdaq Global Market under the symbol "CLLS"
and Cellectis' ordinary shares are listed on the Euronext Growth market
of Euronext in Paris under the symbol "ALCLS".
The Company intends to use the net proceeds from this offering (i) to
establish commercial capabilities, including a proprietary
state-of-the-art gene-edited cell manufacturing plant for commercial
supplies for its current proprietary immuno-oncology UCART product
candidates, (ii) to fund the advancement of one additional UCART product